Takeda TAK
Takeda is a global pharmaceutical company that develops and commercializes innovative medicines in areas such as oncology, gastroenterology, and rare diseases. Takeda shows revenue growth of 10.20% and a pipeline with catalysts such as the priority review of zasocitinib, but its financial health is strained by a net debt/EBITDA of 4.06 and a negative ROE (-2.26), which limits its appeal despite a PEG of 0.43.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Takeda is a global pharmaceutical company that develops and commercializes innovative medicines in areas such as oncology, gastroenterology, and rare diseases. Takeda shows revenue growth of 10.20% and a pipeline with catalysts such as the priority review of zasocitinib, but its financial health is strained by a net debt/EBITDA of 4.06 and a negative ROE (-2.26), which limits its appeal despite a PEG of 0.43.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.6 |
| Quality / Moat | 4.5 |
| Valuation | 5.0 |
| Growth | 4.7 |
| Dividend | 6.3 |
| Momentum | 6.5 |
| Risk & Context | 8.9 |
OVERALL SCORE: 5.5/10
Context and risks
Takeda has significant regulatory and pipeline exposure in the US, where drug pricing pressure is a structural risk for the pharmaceutical sector. Additionally, its high leverage (net debt/EBITDA of 4.06) makes it sensitive to the rate environment, although the main effect is already captured by the engine.
News considered in the analysis
- Takeda Pharmaceutical (TAK) Gets Priority Review. Can Zasocitinib Win in Psoriasis? — La revisión prioritaria de la FDA para zasocitinib en psoriasis es un hito regulatorio material que acelera el potencial de aprobación y comercialización de un activo clave en el pipeline.
- Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry — Noticia sectorial sobre otra empresa; sin impacto directo en Takeda.
- Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects? — Noticia sobre un competidor (Bristol Myers) en la misma área terapéutica; podría implicar mayor competencia, pero sin datos concretos de impacto en Takeda.
- Do Novavax’s (NVAX) New Partnerships Offset Policy Risks From The Protecting Approved Care Act? — Noticia sobre Novavax y riesgos de política sanitaria en EE. UU.; sin impacto directo y material en Takeda.
- Asian Equities Traded in the US as American Depositary Receipts Fall Sharply in Monday Trading — Caída general de los ADR asiáticos, incluyendo probablemente TAK; movimiento de mercado ya reflejado en el precio y sin información fundamental nueva.
Verdict: Hold; the pipeline potential and relative valuation (PEG 0.43) are offset by high leverage and weak return on equity.
Main risk: High leverage (net debt/EBITDA of 4.06) combined with a rising rate environment in the US could increase the cost of debt and further pressure shareholder value creation.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →